ArticleKidney international reports2025
The Protective Effects of SGLT-2 Inhibitors Against Postoperative Acute Kidney Injury in Type 2 Diabetes.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes undergoing surgery: A causal inference study using routinely collected data.Diabetes, obesity & metabolism · 2026Article
- Beyond glycemic control: SGLT2 inhibitors as time-sensitive organ-protective agents in acute injury-mechanistic insights and translational implications.Frontiers in pharmacology · 2026Review
- Busting a Myth: Sodium-Glucose Cotransporter-2 Inhibitors do not Cause Postoperative Acute Kidney Injury.Kidney international reports · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite concerns about the potential of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) to cause acute kidney injury (AKI), recent studies have shown that patients with diabetes on long-term SGLT-2i have lower rates of AKI-related hospitalizations and dialysis. We aimed to assess the real-world preventive effects of SGLT-2i on the risk of postoperative AKI. Methods: We conducted a retrospective study on patients with diabetes who underwent a major surgery at a tertiary hospital in Korea from 2013 to 2023 ( Results: Before matching, the mean age was 67.5 years, with males comprising 66.3% of the cohort. In the matched cohort, the incidence of postoperative AKI was 11.9% in patients on SGLT-2i and 15.1% in those on DPP-4i ( Conclusion: The use of SGLT-2i was independently associated with a lower risk of postoperative AKI than the use of DPP-4i in patients with type 2 diabetes, particularly in high-risk groups such as those with heart failure undergoing cardiovascular surgery. These findings suggest that SGLT-2i may have a role in perioperative AKI prevention in patients with diabetes, although careful monitoring for DKA is advised.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.